Ievie\u0161ot ursodeoksiholsk\u0101bi, Grindeks pl\u0101no iekarot 15% no UDHS pasaules tirgus. Baltijas vado\u0161ais farm\u0101cijas uz\u0146\u0113mums Grindeks sav\u0101 ra\u017eo\u0161an\u0101 ir ieviesis jaunu akt\u012bvo farmaceitisko vielu ursodeoksiholsk\u0101bi (UDHS), kas tiek izmantota gatavo z\u0101\u013cu ra\u017eo\u0161anai aknu un \u017eultsakme\u0146u slim\u012bbu \u0101rst\u0113\u0161an\u0101, Db atkl\u0101ja Grindeks Akt\u012bvo farmaceitisko vielu biznesa strukt\u016bras direktors Andris Jegorovs.<\/p>\n\n\n\n
Grindeks projektu ies\u0101ka 2006. gada beig\u0101s, \u0161o gadu laik\u0101 sekoja intens\u012bvs izp\u0113tes darbs, tehnisk\u0101s un tehnolo\u0123isk\u0101s dokument\u0101cijas izstr\u0101de, bet pag\u0101ju\u0161aj\u0101 gad\u0101 Grindeks veica pirmo pilots\u0113riju pieg\u0101di savam sadarb\u012bbas partnerim V\u0101cijas uz\u0146\u0113mumam \u201eMarenis Pharma\u201d, ar kuru 2008.gada nogal\u0113 tika nosl\u0113gts vair\u0101kpak\u0101pju ilgtermi\u0146a sadarb\u012bbas l\u012bgums.<\/p>\n\n\n\n
\u0160ogad Grindeks sadarb\u012bbas partnerim jau pieg\u0101d\u0101jis pirm\u0101s tr\u012bs r\u016bpniecisk\u0101s s\u0113rijas, kas paredz\u0113tas t\u0101l\u0101kai gatavo z\u0101\u013cu formu ra\u017eo\u0161anai. Grindeks past\u0101v\u012bgas pieg\u0101des \u201eMarenis Pharma\u201d uzs\u0101ks septembr\u012b un l\u012bdz gada beig\u0101m uz\u0146\u0113mums savam sadarb\u012bbas partnerim pl\u0101no pieg\u0101d\u0101t 6-7 tonnas UDHS substances.<\/p>\n\n\n\n
Papla\u0161in\u0101s sadarb\u012bbu<\/strong><\/p>\n\n\n\n Saska\u0146\u0101 ar nosl\u0113gto l\u012bgumu, 2011.gad\u0101 uz\u0146\u0113mumam sadarb\u012bbas partnerim j\u0101pieg\u0101d\u0101 vismaz 30 tonnas UDHS substances, bet 2012. gad\u0101 virs 40 tonn\u0101m.<\/p>\n\n\n\n \u00abTas kopum\u0101 Grindeks akt\u012bvo farmaceitisko vielu biznesu b\u016btiski palielin\u0101s un sp\u0113s pat dubultot,\u00bb nor\u0101da A.Jegorovs, atkl\u0101jot, ka uz\u0146\u0113mumam ir interese pa\u0161am ra\u017eot gatavo z\u0101\u013cu formu, lai n\u0101kotn\u0113 uz\u0146\u0113mums ra\u017eotu ne tikai UDHS substanci, bet ar\u012b gatavo z\u0101\u013cu formu, kas dotu liel\u0101ku pievienoto v\u0113rt\u012bbu. T\u0101p\u0113c \u0161\u0101 gada beig\u0101s Grindeks pl\u0101no turpin\u0101t sarunas ar sadarb\u012bbas partneri par licences sa\u0146em\u0161anu gatavo z\u0101\u013cu formu ra\u017eo\u0161anai, lai uz\u0146\u0113mums paral\u0113li UDHS substances pieg\u0101d\u0113m \u201eMarenis Pharma\u201d var\u0113tu Latvij\u0101 ra\u017eot gatavo z\u0101\u013cu formu.<\/p>\n\n\n\n Gatavo produkciju uz\u0146\u0113mums pl\u0101no eksport\u0113t uz saviem eso\u0161ajiem eksporta tirgiem, jo, k\u0101 nov\u0113rojis Baltijas vado\u0161ais farm\u0101cijas uz\u0146\u0113mums, p\u0113c attiec\u012bg\u0101 medikamenta piepras\u012bjums tikai pieaug, ir br\u012bva tirgus ni\u0161a un labas pe\u013c\u0146as iesp\u0113jas.<\/p>\n\n\n\n 15% no pasaules tirgus<\/strong><\/p>\n\n\n\n \u00abPa\u0161laik pasaul\u0113 konkurentu skaits ir neliels. Kopum\u0101 ir pieci konkurenti: Kan\u0101d\u0101, Jap\u0101n\u0101, Jaunz\u0113land\u0113 un divi It\u0101lij\u0101, un m\u0113s ieejam k\u0101 sestie akt\u012bv\u0101s vielas ra\u017eot\u0101ji,\u00bb akcent\u0113ja A.Jegorovs, atkl\u0101jot, ka Grindeka pl\u0101ns tuv\u0101kajos trijos gados ir aiz\u0146emt 15% no pasaules tirgus. \u00ab\u0160obr\u012bd pasaules kop\u0113jais tirgus tiek prognoz\u0113ts 400-500 t UDHS substances apm\u0113r\u0101, tad m\u0113s ar sav\u0101m 50 t pl\u0101nojam taj\u0101 ieiet,\u00bb t\u0101 A.Jegorovs. UDHS substanci ieg\u016bst no v\u0113r\u0161a \u017eults, kas tiek sav\u0101kta at\u013cautajos re\u0123ionos: t\u0101 n\u0101k no Dienvidamerikas, koncentr\u0113ta tiek Indij\u0101, pirms non\u0101k Latvij\u0101.<\/p>\n\n\n\n Invest\u0113s 6 miljonus<\/strong><\/p>\n\n\n\n \u0160obr\u012bd UDHS substances ra\u017eo\u0161ana notiek Grindeks mazaj\u0101 iecirkn\u012b, taj\u0101 gad\u0101 ir iesp\u0113jams sara\u017eot 16-20 t UDHS substances, bet, \u0146emot v\u0113r\u0101 to, ka Grindeks no 2012. gada ir paredz\u0113jis sara\u017eot ap 50 t akt\u012bv\u0101s farmaceitisk\u0101s vielas, tad, lai nodro\u0161in\u0101tu regul\u0101ru UDHS produkta izstr\u0101di un ra\u017eo\u0161anu, Grindeks uzs\u0101ks jauna ra\u017eo\u0161anas iecirk\u0146a izb\u016bvi. Tam uz\u0146\u0113mums grib piesaist\u012bt ar\u012b ERAF finans\u0113jumu, projekts ir iesniegts Latvijas Invest\u012bciju un att\u012bst\u012bbas a\u0123ent\u016br\u0101 (LIAA) izv\u0113rt\u0113\u0161anai. Eiropas finans\u0113juma piesaiste uz\u0146\u0113muma projektam pal\u012bdz\u0113tu realiz\u0113t daudz \u0101tr\u0101k. Kopum\u0101 ra\u017eo\u0161anas iecirk\u0146a izveidei pl\u0101nots invest\u0113t 6 miljonus latu, no kuriem 45% b\u016btu Eiropas l\u012bdzfinans\u0113jums. Paredz\u0113ts, ka t\u0101 celtniec\u012bba ilgs 1.5-2 gadus, iecirkn\u012b b\u016bs 35 jaunas darbavietas. Ra\u017eo\u0161anas iecirknis b\u016bs izvietots 2 ra\u017eo\u0161anas st\u0101vos un 3 tehniskajos st\u0101vos, kura kop\u0113j\u0101 plat\u012bba b\u016bs 1400 kvadr\u0101tmetru. Pl\u0101nots, ka iecirknis ar pilnu jaudu str\u0101d\u0101s no 2011. gada apr\u012b\u013ca, t\u0101 b\u016bvniec\u012bba s\u0101ksies uzreiz p\u0113c at\u013caujas sa\u0146em\u0161anas LIAA. Ra\u017eo\u0161anas iecirk\u0146a izb\u016bvei Grindeks ir piesaist\u012bjis \u0123ener\u0101luz\u0146\u0113mumu \u010dehu firmu \u201eGMProject\u201d, bet no viet\u0113j\u0101m komp\u0101nij\u0101m projektam izraudz\u012bts SIA \u201eKvadrs\u201d, kas piesaist\u012bs apak\u0161uz\u0146\u0113mumus. Realiz\u0113jot projektu, Grindeks ir paredz\u0113jis ar\u012b palielin\u0101t energoresursu jaudas.<\/p>\n\n\n\n Augs konkur\u0113tsp\u0113ja<\/strong><\/p>\n\n\n\n \u00abAkt\u012bvo farmaceitisko vielu p\u0113tniec\u012bba, izstr\u0101de, ra\u017eo\u0161ana un p\u0101rdo\u0161ana ir viens no Grindeks biznesa virzieniem, kuru p\u0113d\u0113jo gadu laik\u0101 esam m\u0113r\u0137tiec\u012bgi att\u012bst\u012bju\u0161i. Sal\u012bdzino\u0161i ar lielajiem pasaules farm\u0101cijas koncerniem, m\u0113s esam mazs uz\u0146\u0113mums, ta\u010du ieviestais produkts ir v\u0113l viens apstiprin\u0101jums tam, ka m\u0113s esam nopietns tirgus sp\u0113l\u0113t\u0101js un uzticams partneris. Nosl\u0113gtais l\u012bgums palielin\u0101s m\u016bsu konkur\u0113tsp\u0113ju un veicin\u0101s eksporta pieaugumu,\u00bb gandar\u012bts Grindeks valdes priek\u0161s\u0113d\u0113t\u0101js J\u0101nis Romanovskis.<\/p>\n\n\n\n Papla\u0161ina sortimentu<\/strong><\/p>\n\n\n\n UDHS produkta ievie\u0161ana diversific\u0113s Grindeks biznesa darb\u012bbu, k\u0101 ar\u012b papla\u0161in\u0101s uz\u0146\u0113muma produktu portfeli un att\u012bst\u012bbas iesp\u0113jas l\u012bdz \u0161im uz\u0146\u0113mumam piln\u012bgi jaun\u0101 medikamentu terapeitiskaj\u0101 grup\u0101 \u2013 gastroenterolo\u0123isk\u0101s slim\u012bbas.<\/p>\n","protected":false},"excerpt":{"rendered":" Ievie\u0161ot ursodeoksiholsk\u0101bi, Grindeks pl\u0101no iekarot 15% no UDHS pasaules tirgus. Baltijas vado\u0161ais farm\u0101cijas uz\u0146\u0113mums Grindeks sav\u0101 ra\u017eo\u0161an\u0101 ir ieviesis jaunu akt\u012bvo farmaceitisko vielu ursodeoksiholsk\u0101bi (UDHS),…<\/p>\n","protected":false},"author":3,"featured_media":6601,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-628","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunums"],"acf":[],"_links":{"self":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/comments?post=628"}],"version-history":[{"count":0,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/posts\/628\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media\/6601"}],"wp:attachment":[{"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/media?parent=628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/categories?post=628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/grindeks.com\/lv\/wp-json\/wp\/v2\/tags?post=628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}